Hypoglossal Nerve Stimulation and the Incidence of Cardiovascular Disease

Key Findings: A Nuanced Cardiovascular Picture

The study, conducted by researchers at the University of Chicago using the Merative MarketScan Commercial Database from 2015 to 2024, analyzed the health outcomes of 3,786 adults who underwent HGNS implantation and compared them with 3,395 carefully matched controls who met the criteria for HGNS candidacy but did not receive the device. The primary clinical question addressed was whether HGNS is associated with a lower incidence of cardiovascular disease in adults with OSA.

The "bottom line" from this extensive analysis is that while HGNS was associated with a lower hazard of developing new-onset diabetes and hypertension after two years, its impact on major cardiovascular events within the same timeframe was less clear. Intriguingly, the study also found a higher risk of hypertension and minor cardiovascular events within the first two years of treatment. This suggests a dynamic effect, with potential benefits emerging over a longer duration.

Understanding Obstructive Sleep Apnea and its Cardiovascular Burden

Obstructive Sleep Apnea (OSA) is a widespread and serious sleep disorder affecting millions in the United States. It is characterized by repeated episodes of partial or complete blockage of the upper airway during sleep, leading to intermittent hypoxia (low oxygen levels) and sleep fragmentation. The consequences of untreated OSA extend far beyond daytime sleepiness and fatigue; it is a significant risk factor for a cascade of serious cardiovascular conditions, including atrial fibrillation, stroke, heart failure, coronary artery disease, diabetes, hypertension, and myocardial infarction, ultimately increasing the risk of premature death.

The established first-line treatment for OSA is positive airway pressure (PAP) therapy, typically continuous positive airway pressure (CPAP). While effective in managing airway obstruction, PAP therapy often suffers from poor long-term adherence. Many patients find the masks uncomfortable, experience air leaks, or have difficulty tolerating the pressure, leading to inconsistent use and diminished therapeutic benefit.

This challenge has paved the way for alternative treatments, such as HGNS. Approved by the U.S. Food and Drug Administration (FDA), HGNS involves implanting a device that stimulates the hypoglossal nerve, which controls the tongue and other muscles of the upper airway. By stimulating these muscles, the device prevents the airway from collapsing during sleep, thereby improving breathing and reducing the frequency and severity of apneas. HGNS has demonstrated higher adherence rates compared to PAP and has shown significant improvements in objective measures like the apnea-hypopnea index (AHI) and subjective patient-reported outcomes. However, its precise long-term effects on cardiovascular health have remained a subject of ongoing investigation.

Methodology: A Robust Retrospective Cohort Study

The researchers employed a retrospective cohort study design, a common approach for analyzing real-world data from large administrative claims databases. The Merative MarketScan Commercial Database provided a rich source of de-identified health insurance claims data, encompassing a broad spectrum of commercial insurance enrollees in the U.S.

The study meticulously matched patients who underwent HGNS implantation with a control group of OSA patients who met the eligibility criteria for HGNS but did not receive the device. Eligibility criteria for HGNS typically include a diagnosis of moderate to severe OSA confirmed by a sleep study and a history of nonadherence to PAP therapy. This matching process was crucial for minimizing bias and ensuring that the two groups were as comparable as possible at baseline. The matching accounted for various factors, including demographics, pre-existing comorbidities, duration of diagnosed OSA, and the year of their index event (either HGNS implantation or the start of the observation period for controls).

A key aspect of the study’s design was modeling HGNS as a time-varying covariate. This sophisticated statistical approach allowed researchers to differentiate the effects of HGNS during the initial period after implantation (within two years) and in the subsequent period (after two years). This is particularly important given the potential for treatments to have different impacts over time.

Detailed Findings: Unpacking the Cardiovascular Outcomes

The HGNS cohort comprised 3,786 adults, with approximately 67.7% being male and a median age of 53.0 years. Following propensity score matching, 3,395 HGNS patients were compared to an equal number of matched controls. The matching process yielded excellent balance across demographics, comorbidities, and prior cardiovascular history, bolstering the reliability of the findings.

Diabetes and Hypertension: An Emerging Protective Trend

One of the most encouraging findings emerged from the subgroup of patients without pre-existing cardiovascular disease. Within the first two years of treatment, HGNS was not significantly associated with a new diagnosis of diabetes (hazard ratio [HR], 1.06; 95% confidence interval [CI], 0.61 to 1.85). However, the picture changed dramatically after the two-year mark. In this later period, HGNS was associated with a substantially lower hazard of incident diabetes (HR, 0.19; 95% CI, 0.09 to 0.38). This suggests a potential disease-modifying effect of HGNS on the development of diabetes over the longer term.

Similarly, for hypertension, the early impact of HGNS appeared to be less favorable. Within the first two years, HGNS was associated with a higher hazard of hypertension diagnosis (HR, 1.70; 95% CI, 1.26 to 2.28). This could potentially be attributed to the physiological adjustments the body undergoes following the implantation and activation of the device, or perhaps reflect increased medical surveillance in patients receiving a new implant. However, as with diabetes, this trend reversed after two years. HGNS was associated with a significantly lower hazard of hypertension diagnosis after the two-year mark (HR, 0.49; 95% CI, 0.33 to 0.73), indicating a protective effect over extended use.

Cardiovascular Events: An Initial Increase Followed by a Declining Trend

The impact of HGNS on established cardiovascular events presented a more complex narrative, particularly in patients with pre-existing diabetes or hypertension. Within the first two years of HGNS treatment, the study observed a higher hazard of diagnoses for minor cardiovascular events, defined as cardiac arrhythmia or coronary artery disease (HR, 1.44; 95% CI, 1.06 to 1.95). Furthermore, there was a higher hazard of major cardiovascular events, including cerebrovascular disease, heart failure, or myocardial infarction, within this initial two-year period (HR, 1.62; 95% CI, 1.06 to 2.48).

This finding of an increased risk of cardiovascular events in the early stages warrants careful consideration. It is possible that the initial period after surgery and device activation could be associated with a transient inflammatory response or other physiological stressors that might temporarily elevate cardiovascular risk. Additionally, patients undergoing HGNS implantation may have had more severe OSA or more advanced underlying cardiovascular disease, contributing to these early events.

However, the long-term outlook for cardiovascular events also showed a promising trend. After two years, HGNS was not significantly associated with a higher hazard of minor cardiovascular events (HR, 0.60; 95% CI, 0.35 to 1.04) or major cardiovascular events (HR, 0.65; 95% CI, 0.31 to 1.36). While these associations did not reach statistical significance at the conventional p<0.05 level, the hazard ratios were consistently below 1, suggesting a trend towards fewer events. Moreover, when analyzed using time-varying models that capture ongoing effects, the hazards for both minor (HR, 0.42; 95% CI, 0.22 to 0.79) and major cardiovascular events (HR, 0.40; 95% CI, 0.17 to 0.93) showed statistically significant decreasing trends after two years. This reinforces the notion that the cardiovascular benefits of HGNS may indeed materialize over extended periods of use.

Study Limitations and Future Directions

The researchers acknowledge several limitations inherent in this retrospective claims-based study. Crucially, the severity of OSA, as measured by AHI, was not consistently available in the claims data. Similarly, detailed cardiovascular markers and information on race/ethnicity were not consistently captured. These missing data points could potentially influence the observed associations. The study design also carries the risk of residual confounding, where unmeasured factors might influence both the decision to undergo HGNS and the subsequent cardiovascular outcomes. Surveillance bias, where patients receiving a new implant might be more closely monitored and thus more likely to have conditions diagnosed, is another potential concern.

Despite these limitations, the study’s large sample size, rigorous matching procedures, and the use of time-varying models provide valuable insights into the real-world cardiovascular impact of HGNS.

Broader Impact and Implications for Clinical Practice

The findings of this study have significant implications for both clinicians and patients considering HGNS for OSA management. The observed pattern suggests that HGNS is not a panacea with immediate universal cardiovascular benefits. Instead, it points towards a more nuanced, time-dependent effect.

The initial increase in the hazard of hypertension and cardiovascular events within the first two years highlights the importance of careful patient selection and close post-operative monitoring. Patients with existing cardiovascular disease or those at high risk may require enhanced vigilance and proactive management strategies during this period.

Conversely, the emerging benefits in reducing the incidence of diabetes and hypertension, and the decreasing trends in cardiovascular events after two years, offer a compelling rationale for long-term HGNS use. This underscores the need for sustained adherence to the therapy, similar to other chronic disease management strategies.

The study’s conclusion that "the observed patterns indicate variability but suggest potential long-term cardiovascular benefits of HGNS" is a measured yet optimistic assessment. It calls for further research to confirm these associations and to better understand the underlying biological mechanisms that might mediate these effects. Prospective, randomized controlled trials with longer follow-up periods and detailed physiological measurements would be invaluable in solidifying these findings and refining clinical guidelines.

In essence, the study contributes to a growing body of evidence suggesting that HGNS, while not without its early-stage complexities, may offer a valuable therapeutic option for managing OSA and, over time, contribute to improving the cardiovascular health of a significant patient population. The ongoing evolution of this treatment’s cardiovascular profile emphasizes the dynamic nature of medical interventions and the critical importance of long-term follow-up in assessing their true impact.